Trials / Completed
CompletedNCT00088140
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
A Dose Response Study of a Caspase Inhibitor in Hepatitis C Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 204 (actual)
- Sponsor
- Conatus Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDN-6556 | |
| DRUG | Placebo |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2004-07-21
- Last updated
- 2012-08-13
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088140. Inclusion in this directory is not an endorsement.